EXPLORE PTEROIS THERAPEUTICS SOLUTIONS
At Pterois Therapeutics, we are redefining cancer treatment by unlocking the therapeutic potential of marine biodiversity. Our innovative platforms transform the venom of Pterois volitans into next-generation solutions — from natural bioactives to advanced biotechnologies — designed to fight resistant cancers, improve patient outcomes, and contribute to a more sustainable future.
CHOOSE YOUR TRACK
At Pterois Therapeutics, we understand that every partner has unique goals and challenges. That’s why we offer tailored collaboration pathways designed to match the specific needs of your sector — whether you’re in biopharma, academic research, clinical development, investment, or environmental innovation.
Our flexible partnership models help you integrate our marine-based technologies into your own strategies, accelerate innovation, and maximize real-world impact.
01
Biopharma Track
Partner with us to co-develop next-generation oncology therapies. From early-stage discovery to clinical development, we offer access to unique marine-derived compounds, cutting-edge platforms, and translational expertise.
02
Research & Academia Track
Collaborate on breakthrough science. Our advanced extraction, purification, and molecular characterization technologies are available for joint research, publications, and innovation programs with universities and research centers.
03
Investment & Venture Track
Invest in the future of precision oncology. We provide structured opportunities for venture partners and strategic investors to support the development of disruptive therapies with strong market potential and global impact.
04
Sustainability & Innovation Track
Join us in transforming an ecological challenge into a medical solution. Together, we can create circular value by integrating marine biodiversity, environmental restoration, and cutting-edge biotechnology.
We're good with numbers
$2.5+ billion
Estimated global market potential for marine-derived oncology therapies by 2030
+150 million
Cancer patients worldwide who could benefit from next-generation targeted treatments
>90 %
Tumor growth inhibition observed in vitro with our lead compound
